Disarm Therapeutics Appoints Veteran Biotech Executive Scott Holmes as Chief Financial Officer
CAMBRIDGE, Mass., Jan. 13, 2020 – Disarm Therapeutics, a biotechnology company creating a new class of disease-modifying therapeutics for patients with axonal degeneration, today announced the appointment of Scott Holmes, M.S./MBA, as Chief Financial Officer. Holmes comes to Disarm from Kiadis Pharma, where he served as Chief Financial Officer and member of the Management Board. He has nearly 20 years of finance, strategy, and operations experience in the biotechnology industry.
“Scott joins our team at a critical and exciting time, as we have made significant progress in our efforts to develop disease-modifying therapies that address axonal degeneration,” said Alvin Shih, M.D., Disarm’s President and CEO. “His deep industry experience will be a valuable asset as we continue to advance our programs to treat neurodegenerative diseases such as MS, ALS, and peripheral neuropathy.”
“Disarm’s approach to developing therapeutics that target SARM1 is highly compelling and is made possible by the team’s deep and unique knowledge of the protein and the role it plays in neurodegeneration,” Holmes said. “I look forward to guiding the company’s fundraising efforts and financial strategy as we work to bring transformative therapies to patients in need.”
Holmes was responsible for all financial operations at Kiadis Pharma, including leading the company’s acquisition of CytoSen Therapeutics, Inc. Previously, he spent four years as Chief Financial Officer of Keryx Biopharmaceuticals, where he executed multiple high-value financial offerings and oversaw the merger of Keryx into Akebia Therapeutics, Inc. Holmes was also previously Senior Vice President of Finance and Investor Relations at AMAG Pharmaceuticals, Inc. He holds a B.A. in History from Middlebury College and an M.S./MBA from Northeastern University.
About Disarm Therapeutics
Disarm Therapeutics is a biotechnology company that is creating a new class of disease-modifying therapeutics for patients with axonal degeneration, a central driver of neurological disability and disease progression. By inhibiting the SARM1 protein, identified by the company’s scientific founders as the central driver of axonal degeneration, these therapeutics may prevent the loss of axons in chronic and acute diseases of the central, ocular, and peripheral nervous systems. For a broad range of diseases including multiple sclerosis, amyotrophic lateral sclerosis, glaucoma, and peripheral neuropathies, the therapeutic goal is to prevent further degeneration, stabilize disease, and allow for functional recovery. Disarm was founded by Atlas Venture, Dr. Jeffrey Milbrandt and Dr. Aaron DiAntonio of Washington University in St. Louis, and a team of exceptional scientists and drug developers committed to developing a new treatment paradigm for patients with neurological diseases. For more information, please visit www.disarmtx.com.
Stephanie Simon, Ten Bridge Communications